• CDT Equity posted a net loss of USD 4.64 million for the quarter ended June 30, 2026, narrowing from USD 6.03 million.
• Operating loss narrowed to USD 3 million from USD 4.95 million, as operating expenses fell to USD 3 million from USD 4.95 million.
• Research and development expense dropped 84% to USD 302,000, due to lower Sarborg-related activity and reduced Thesprogen agreement costs.
• General and administrative expense decreased 13% to USD 2.7 million, on lower legal and professional fees, salaries and stock-based compensation, and insurance.
• Other expense widened to USD 1.54 million from USD 1.02 million, driven by convertible note fair-value and conversion-related items.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037458), on August 12, 2026, and is solely responsible for the information contained therein.